Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
City of Hope Medical Center
Eli Lilly and Company
University of Arizona
Jonsson Comprehensive Cancer Center
British Columbia Cancer Agency
Hoffmann-La Roche
Eli Lilly and Company